-
Fujifilm Announces Financial Results for the Third Quarter of Fiscal Year 2021
Time of Update: 2022-03-06
In order to accelerate the creation of synergies within the group and provide more value to the printing industry on a global scale, the company will combine the production services originally included in "document processing" with the printing services included in "health care and high-performance materials".
-
The clinical trial application of 8MW2311 for innovative drug injection of Maiwei Bio has been accepted by NMPA
Time of Update: 2022-03-06
15, 2022 /PRNewswire/ -- Maiwei Bio (stock code: 688062), an innovative biopharmaceutical company with a full industrial chain layout, announced that the clinical trial application of its self-developed 8MW2311 for injection has won the national drug The Supervisory Authority (NMPA) accepts .
-
Qilu Pharmaceutical sprints domestic nintedanib, the second nintedanib sales exceed 600%
Time of Update: 2022-03-06
Sales of nintedanib ethanesulfonate soft capsules in Chinese urban physical pharmacies in recent years (unit: ten thousand yuan) Source: Minet.
Sales of nintedanib ethanesulfonate soft capsules in Chinese urban physical pharmacies in recent years (unit: ten thousand yuan) Source: Minet.
-
CStone Pharmaceuticals Announces Acceptance of New Drug Applications for Pratinib in Taiwan, China
Time of Update: 2022-03-05
<> /* Style Definitions */ span. prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a. prnews_a { color:blue; } li. prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p. prne
-
Sinopharm Modern Esomeprazole Sodium for Injection Approved
Time of Update: 2022-03-05
On February 17, Sinopharm Modern announced that its wholly-owned subsidiary Sinopharm Rongsheng's esomeprazole sodium for injection (40mg) was approved, which can be used as an alternative therapy for gastroesophageal reflux disease when oral therapy is not applicable.
-
Innovent Biologics Announces Two Pivotal Registration Clinical Studies of IBI306 (PCSK-9 Inhibitor) Meeting Primary Endpoints
Time of Update: 2022-03-05
The results of the CREDIT-1 study showed that in Chinese non-familial hypercholesterolemia (non-FH) patients with high-risk/very high-risk cardiovascular risk, after 48 weeks of continuous treatment with each dose group of IBI306, low-density lipoprotein cholesterol (LDL- C) Compared with the baseline reduction level, there was a significant improvement compared with the placebo group (450mg Q4W group: the difference between the groups by least squares estimate was -65.
-
HPG: Green tea catechins make a new breakthrough in virus inactivation
Time of Update: 2022-03-05
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.
pdf - This ingredient has an inactivation effect on the new coronavirus and SARS (infectious atypical pneumonia) virusDetails: https://kyodonewsprwire.
-
Closely follow the application needs of infection + reproductive genetic diagnosis, and grasp the new future of molecular diagnosis technology!
Time of Update: 2022-03-03
As the fastest-growing segment of the IVD industry, molecular diagnostics is supported by the explosive industry enthusiasm and market education and national policies. How to crack the layout of "ine
-
WuXi Biologics' stock solution production base completed the GMP audit of the Korean Ministry of Food and Drug Safety
Time of Update: 2022-02-22
HK), the world's leading open biopharmaceutical technology platform company , announced that it has successfully completed the Korean Ministry of Food and Drug Safety (MFDS) Remote GMP inspection of its Wuxi raw liquid production base Raw Liquid No.
-
The new coronavirus mRNA vaccine independently developed by RiboBio and Agna Biopharmaceuticals has started clinical trials
Time of Update: 2022-02-22
With the support of the government's new crown emergency research project, Ribo Bio, Agna Biopharmaceutical, the Guangzhou Institute of Biomedicine and Health of the Chinese Academy of Sciences and the Guangzhou National Laboratory carried out scientific research cooperation, and jointly carried out the mRNA of the original strain and variant strain of the new coronavirus Vaccine development and production .
-
Philippines Approves RecoBio's New Coronary Pneumonia Vaccine ReCOV for Phase II/III Clinical Study
Time of Update: 2022-02-22
62em; font-family:"Arial"; color:black; margin:0in; } The recombinant two-component new crown vaccine ReCOV has been approved to enter the international phase II/III clinical study The recombinant two-component new crown vaccine ReCOV has good cross-neutralization effect on VOC mutants such as Omicron and Delta Ricogi Bio, a subsidiary focused on mRNA infectious disease vaccines, launched the world's first lyophilized mRNA vaccine TAIZHOU, Jan.
-
Beihai Kangcheng's new drug CAN108 for the treatment of Alagille syndrome has been officially accepted by the National Medical Products Administration (NMPA) and will be included in priority review
Time of Update: 2022-02-22
Under the terms of the agreement, Beihai Kangcheng has obtained an exclusive license to develop and commercialize three indications in Greater China for Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia (BA).
-
2021 Top Ten Innovative Products in Life Science Announced
Time of Update: 2022-02-22
The emergence and breakthrough of technologies such as genome editing, microscopic imaging, single-cell analysis, and spatial transcriptomics have enabled the field of life science to develop higher, faster, and stronger, and have also enabled scientists to better answer questions related to health and disease.
-
CStone Pharmaceuticals Announces Completion of Subject Enrollment in Two Phase III Registration Clinical Trials of Zejimet(R) (Sugelimab Injection)
Time of Update: 2022-02-22
prnsbr0{ BORDER-RIGHT:0pt } First-line Combination Chemotherapy for Gastric /Gastroesophageal Junction Adenocarcinoma and Esophageal Squamous Cell Carcinoma Following the approval of Zejimei (R) in mainland China for the first-line treatment of stage IV non-small cell lung cancer (NSCLC), the successful submission of the marketing application for stage III NSCLC and the achievement of the primary endpoint of the registration clinical study for the treatment of relapsed and refractory lymphoma , another important progress of CStone's product R&D pipeline SUZHOU, Jan.
-
Soaring 400% injection!
Time of Update: 2022-02-21
Source: CDE official website, Minet database A few days ago, the CDE official website showed that the neostigmine methyl sulfate injection of Chengdu Yuandong Biopharmaceutical was accepted as a 3-type imitation .
-
Biopharmaceutical companies join hands with new R&D institutions: to promote the transformation of hematopoietic stem cell regeneration therapy
Time of Update: 2022-02-19
In 2021, Boya Jiyin initiated a phase I multicenter clinical trial of ET-01, the first gene-edited hematopoietic stem cell therapy research product for transfusion-dependent β-thalassemia in China, and was conducted in the Hematology Hospital of the Chinese Academy of Medical Sciences (Chinese Academy of Medical Sciences).
-
Manulife survey shows that mainland Chinese consumers are more optimistic about the outlook for the epidemic
Time of Update: 2022-02-18
”The demand for pensions continues to increase , and highly customized insurance products are more popular The survey results show that mainland consumers tend to respond to the impact of the epidemic through more active financial planning, and 77% of mainland respondents believe that insurance has become more important since the outbreak .
-
5 billion new dosage forms of antihypertensive drugs!
Time of Update: 2022-02-18
Sales of terminal valsartan in physical pharmacies in Chinese cities (unit: 10,000 yuan) Source: Minet.
Sales of terminal valsartan in physical pharmacies in Chinese cities (unit: 10,000 yuan) Source: Minet.
Sales of terminal valsartan in physical pharmacies in Chinese cities (unit: 10,000 yuan) Source: Minet.
-
By-Health donated 6.7 million yuan of nutritional products and partners to support Xi'an and Zhuhai to fight the epidemic
Time of Update: 2022-02-18
to assist Xi'an in fighting the epidemic, and through the Shaanxi Red Cross Society Medical staff and community epidemic prevention volunteers in Xi'an donated 50,000 boxes of Tomson By-Health Vitamin C Effervescent Tablets (sweet orange flavor), with a total market price of more than 4.
-
SGS issues the industry's first Greenhouse Gas Emissions Verification Statement Certificate to Huada Group
Time of Update: 2022-02-18
This time, it successfully obtained the ISO 14064-1:2018 Greenhouse Gas Emissions Verification Statement Certificate issued by the international authoritative third-party organization SGS, which has played a good role in demonstrating the green and low-carbon development of the industry .
